Discovery & history

• Where BPC-157 came from and what the "body protection compound" story actually means
• The mechanisms it is proposed to touch, from the NO system to FAK-paxillin signaling
• How to weigh a literature dominated by a single research lineage
• What the regulatory status (WADA, FDA 503A) and safety evidence really say

1. 01 Discovery & history A fragment of gastric juice that grew an outsized reputation free
2. 02 The molecule and its structure Fifteen residues, four prolines, and a famous stability claim paid
3. 03 Vascular mechanisms: nitric oxide and angiogenesis The two vascular stories BPC-157 tells best paid
4. 04 Growth-factor and kinase signaling The signaling behind the healing claims paid
5. 05 Gut healing: the original domain Where the BPC-157 story actually began paid
6. 06 Tendon and ligament repair The cleanest mechanistic story, and the one most over-sold to athletes paid
7. 07 Skin and wound healing Faster, better-organized skin repair, in rodents paid
8. 08 Nerve, brain, and beyond The broad, speculative end of the BPC-157 story paid
9. 09 Dosing & Administration What the community does, and why none of it is a protocol paid
10. 10 Safety & regulatory status A reassuring preclinical package, a near-empty human record, and a hard legal line paid
11. 11 Reading the evidence honestly An unusually deep preclinical story with an unusually shallow clinical base paid
12. 12 Final Exam & Certification Pass the final exam to earn your specialist certificate. exam

BPC-157 did not come from a drug-design program. It came from the idea that the stomach protects itself, and that the molecules doing the protecting might help the rest of the body too. The Zagreb group framed gastric juice as a source of organ-protective peptides and synthesized BPC-157 as a representative, reproducible sequence.

Notice what is missing from that timeline: a published human efficacy trial. The field has accumulated mechanism papers and rat models for thirty years, yet the closest thing to human data remains a single phase 1 safety abstract. That mismatch is the throughline of this whole course.

Strip away the marketing and BPC-157 is a short synthetic chain of fifteen amino acids. It is not a hormone, not a natural standalone peptide, and not isolated from the body in this form. It is a fragment that researchers selected and synthesized because it reproduced a protective effect.

The full sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. That proline-heavy, charge-balanced makeup is what the lab credits for its unusual stability, and the triple-proline run is the structural feature later mechanism hypotheses lean on.

BPC-157 is sold in the same "recovery peptide" niche as a few others. Seeing them side by side clarifies what is actually distinctive about it, and where it is simply less characterized than the alternatives.

The pattern is revealing. BPC-157 has the widest range of preclinical claims but the least defined molecular target, while TB-500, GHK-Cu, and KPV all have identified mechanisms. None of the four has a controlled human efficacy trial in soft-tissue recovery, which is worth remembering whenever one is marketed as proven.

The most important thing to understand before any mechanism slide is where the evidence comes from. The great majority of original BPC-157 papers list Sikiric or Seiwerth as a first or senior author, and most "replications" trace back into the same lineage.

This is not an accusation that the work is wrong. It is a reminder that science gains confidence through independent replication, and that a field built largely by one group has not yet earned that confidence. Keep this caveat in mind every time a later unit describes a mechanism or a healing result.

Before the deeper science, here is the honest map of what is well supported versus merely hopeful. The point of this course is to keep these tiers apart instead of rounding everything up to "proven."

The gap between the green tiers and the red ones is the entire subject of this course. The rat-level mechanism work is genuinely substantial, and that is exactly why honest framing matters: a strong preclinical story is the easiest kind to over-sell as a human result.

A few specific claims you will meet online, held against the evidence tiers above. Most are not flatly false, they are real but modest preclinical findings rounded up into certainty.

Reading each claim against its actual tier is the core skill this course builds. By the final exam you should be able to take any BPC-157 marketing sentence and place it on this map yourself.